The First Crispr Treatment Is Making Its Way to Patients
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder. It’s finally being infused into patients.
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder. It’s finally being infused into patients.
